Champions Oncology, Inc. announced its financial results for the fiscal year and fourth quarter ended April 30, 2025, on July 23, 2025. The company reported record annual revenue of $57 million for fiscal year 2025, representing a 14% increase year-over-year from $50.2 million in fiscal 2024.
The company achieved a net income of $4.6 million for fiscal 2025, a significant turnaround from a net loss of $7.28 million in fiscal 2024. Adjusted EBITDA income for the year was $7.1 million, compared to an adjusted EBITDA loss of $3.9 million in the prior year. Data license revenue contributed $4.7 million to the annual total.
For the fourth quarter of fiscal 2025, total revenue was $12.3 million, with an Adjusted EBITDA loss of $1.2 million and new data licensing revenue of approximately $200,000. The company ended the fiscal year with a cash balance of $9.8 million, up from $2.6 million a year prior, and generated $7.4 million in cash flow from operations for the twelve months ended April 30, 2025. CEO Ronnie Morris stated that the past year was pivotal, marked by a return to growth and profitability and the launch of a high-margin data business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.